JP Morgan Chase’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

JP Morgan Chase’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-310,000	Closed	-$28.2M	–	7466
2023 Q1	$28.2M	Buy	+310,000	New	+$18.2M	﹤0.01%	1412

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's RETA Position: Q3 2023 in Review

JP Morgan Chase sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 206,223 shares — an estimated $21M sold.

JP Morgan Chase first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $21M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

JP Morgan Chase reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
JP Morgan Chase sold 206,223 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $21M.
JP Morgan Chase first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
JP Morgan Chase's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $21M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.